An update on the management of sporadic desmoid-type fibromatosis: a european consensus initiative between sarcoma patients euronet (spaen) and european organization for research and treatment of cancer (eortc)/soft tissue and bone sarcoma group (stbsg)

Archive ouverte

Kasper, Bernd | Baumgarten, C. | Garcia, J. | Bonvalot, Sylvie | Haas, R. | Haller, F. | Hohenberger, P. | Penel, Nicolas | Messiou, C. | van Der Graaf, W. T. | Gronchi, A.

Edité par CCSD ; Elsevier -

International audience. Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European Desmoid Working Group published a position paper giving recommendations on the treatment of this intriguing disease. Here, we present an update of this consensus approach based on professionals' AND patients' expertise following a round table meeting bringing together sarcoma experts from the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group with patients and patient advocates from Sarcoma PAtients EuroNet. In this paper, we focus on new findings regarding the prognostic value of mutational analysis in desmoid-type fibromatosis patients and new systemic treatment options.

Suggestions

Du même auteur

Best practices for the management of local-regional recurrent chordoma: a position paper by the chordoma global consensus group

Archive ouverte | Gronchi, A. | CCSD

International audience. Chordomas are rare, malignant bone tumors of the skull-base and axial skeleton. Until recently, there was no consensus among experts regarding appropriate clinical management of chordoma, res...

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Archive ouverte | Bellera, C. | CCSD

International audience

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS)

Archive ouverte | Casali, P. G. | CCSD

International audience. BackgroundIn 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk gastrointestinal stromal t...

Chargement des enrichissements...